Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences Inc (NQ: AURA )

13.77 -0.13 (-0.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,268
Open 13.51
Bid (Size) 10.00 (30)
Ask (Size) 15.02 (3)
Prev. Close 13.90
Today's Range 12.74 - 13.91
52wk Range 11.98 - 26.16
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tesla, ABB And Other Big Losers From Monday
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga

Performance

YTD
-26.72%
-26.72%
1 Month
-0.58%
-0.58%
3 Month
-10.00%
-10.00%
6 Month
-30.17%
-30.17%
1 Year
-6.96%
-6.96%

More News

Read More
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
Via Benzinga
JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
Via Benzinga
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
From Aura Biosciences Inc.
Via Business Wire
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
From Aura Biosciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
Via Benzinga
Aura Biosciences' Stock Gains As FDA Grants Fast Track Status To Bladder Cancer Drug
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Via Benzinga
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.